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CASE PRESENTATION
A 75-year-old Caucasian man with hypertension and severe,
emphysema, presented to the Veterans Administration
New York Harbor Health Care System Hospital outpatient
clinic, for his bi-yearly physical in March 2003. The patient
had a macrocytic anemia and a serum creatinine (Scr) level of
3.3 mg per 100 ml (baseline Scr, 0.9 mg per 100 ml 1 month
earlier). An outpatient nephrology consultation was initiated
after a comprehensive negative gastrointestinal workup.
Detailed history and physical examination were performed.
He denied the following symptoms: headache, visual
changes, hesitancy, frequency, oliguria, dysuria, nausea,
vomiting, fever, chills, bone pain, and change in weight,
appetite or bowel habits. He also denied the following:
hematochezia, melena, fatigue, dyspnea, dizziness, or chest
pain. His medications on presentation included lisinopril
20 mg day1 and combination albuterol and atrovent inhaler.
He denied occupational or chemical exposure, and use of
herbal or over-the-counter medications. The patient quit
smoking and drinking over 20 years ago. He had no history
of diabetes mellitus, macroscopic hematuria, or tuberculosis.
His family history was non-contributory. Physical examination
revealed an alert, healthy-appearing older male with a blood
pressure of 134/83 mm Hg (without orthostasis), pulse rate of
78 beats min1, weight of 89 kg, and body mass index of
29 kg m2. There was no lymphadenopathy. Heart
examination showed regular rate and rhythm, without
murmurs, rubs, or gallops. Lungs were clear to percussion
and auscultation. Abdomen had normal bowel sounds, was
soft, non-tender, with no masses or hepatomegaly.
There was dullness in Traube’s space on deep inspiration.
Extremities revealed no clubbing, cyanosis, rash, or
edema. Neurological examination was essentially normal.
Diagnostic studies were performed. Renal ultrasound
showed 11.7 and 12.4 cm right and left kidney,
respectively. Both kidneys demonstrated mildly increased,
diffuse parenchymal echogenicity, consistent with mild
medical renal disease, with no scarring or masses. There
was no hydronephrosis. Renal veins were patent
bilaterally. The bladder was not distended. Spleen was
enlarged, measuring 12.6 cm. Results of the laboratory
studies are detailed in Table 1. Urinary dipstick showed
trace protein but sulfosalicyclic acid testing was not
performed. Twenty-four-hour urine protein level was
3.1 g day1. Urine protein electrophoresis was
unremarkable, but urine and serum immunofixation
electrophoresis and serum protein electrophoresis
showed a monoclonal band (IgAk). His quantitative serum
immunoglobulin A (IgA) level was 2330 mg per 100 ml.
Bone marrow biopsy revealed 90% plasma cells (Figure 1).
Skeletal survey was negative. A diagnosis of multiple
myeloma (MM) Durie–Salmon stage III was made.
CLINICAL COURSE
The patient’s age and comorbidities precluded consideration of
stem cell transplant. Initial therapy was directed at correcting
reversible factors contributing to a reduction in glomerular
filtration rate (GFR), which included discontinuation of
lisinopril and volume expansion. Blood pressure was thereafter
managed with a b-blocker. Concurrent treatment with
thalidomide and dexamethasone was started. On this regimen,
reductions in serum creatinine (Scr) levels to 1.2 mg per 100 ml
and serum immunoglobulin A (IgA) to 121 mg per 100 ml
occurred within several months. Thalidomide was discontin-
ued after 6 months because of severe peripheral neuropathy.
Two years later (August 2005), serum IgA level increased
to 767 mg per 100 ml and Scr reached 1.7 mg per 100 ml.
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Having relapsed, the patient was started on melphalan and
prednisone. Over the next month, the IgA levels plateaued.
However, chemotherapy was discontinued because of pro-
found neutropenia and pneumonia requiring hospitalization.
In February 2006 (2.5 years following the original diagnosis),
the patient was hospitalized for both respiratory and urinary
infections, and was again found to have disease recurrence.
Repeat bone marrow biopsy at that time showed 90% plasma
cells. Serum IgA level was 2403 mg per 100 ml, with
proteinuria level of 2.4 g day1 and Scr of 4 mg per 100 ml.
B2-microglobulin was 30 mg per 100 ml. Corrected serum
calcium and uric acid levels were 8.9 and 7.4 mg per 100 ml,
respectively. In addition to antibiotic treatment for his
infections, his acute-on-chronic renal failure was treated with
bicarbonate alkalinization to maintain a urine pH 46.5 and
volume expansion to sustain a urine output 42 l day1.
Despite these measures, the patient developed anuria and a
Scr level of 7.5 mg per 100 ml. This observation, and the need
for blood products to treat a new spontaneous retro-
peritoneal bleed, prompted temporary hemodialysis (HD)
initiation. A renal biopsy detailed below, showed myeloma
cast nephropathy (MCN) (Figure 2). Plasmapheresis was
started, resulting in reduction in serum IgA, Scr, and
improvement in urinary output. Chemotherapy was post-
poned until infection resolved. After 10 sessions of alternate-
day plasmapheresis with fresh frozen plasma, IgA level
declined roughly 50% from 2403 to 1329 mg per 100 ml
(Figure 3). Dialysis was discontinued after two HD sessions,
when the patient became non-oliguric and Scr stabilized at
3.7 mg per 100 ml. Two months later (April 2006), triple
therapy with bortezomib, thalidomide, and dexamethasone
was started. The IgA level and renal function did not improve
further despite chemotherapy.
Three years following diagnosis of multiple myeloma
(MM) (June 2006), he was readmitted with weakness and
hypotension. He had serum-k free light chain (sFLC) levels
of 1180 mg per 100 ml, IgA of 1917 mg per 100 ml, and was
developing worsening non-oliguric renal failure (Scr 5.7 mg
Table 1 | Laboratory data at initial nephrology consultation
Variables
Reference
values
Patient’s
value
Blood
Na (mEq l1) 135–145 138
K (mEq l1) 3.5–5 5.0
Cl (mEq l1) 100–110 100
HCO3 (mEq l
1) 24–32 21
Anion gap 3–11 17
Serum blood urea nitrogen (mg per 100 ml) 4.4–22 45
Serum creatinine (mg per 100 ml) 0.4–1.2 3.3
Corrected calcium (mg per 100 ml) 8.4–10 10.1
Protein (g per 100 ml) 6.4–8.2 6.8
Albumin (g per 100 ml) 3.8–5.1 3.4
White blood cells ( 109 l1) 4.5–11 5.4
Hemoglobin (g per 100 ml) 13–18 8.1
Platelets ( 109 l1) 141–320 120
Mean corpuscular volume (fl) 80–95 102
Uric acid (mg per 100 ml) 2.1–8.5 8.0
B2-microglobulin (mg per 100 ml) o2.4 19
C-reactive protein-HS (mg per 100 ml) 0.12–0.5 1.1
Lactate dehydrogenase (U l1) 91–180 459
Serum protein electrophoresis (m—spike) IgA
Immunofixation electrophoresis IgAk
k-Serum free light chains (mg per 100 ml) NA
Quantitative immunoglobulin-A
(mg per 100 ml)
2330
Urine
24-h urine protein (g day1) 3.1
Urinalysis: Specific gravity 1.012, no blood, ketones,
bilirubin, or glucose. Grade-1+ protein
Microscopic examination: Two white blood cells per high-power
field, 1(non-dysmorphic) red blood cell per high-power field,
0 casts per high-power field
Protein electrophoresis (m—spike) Negative
Immunofixation electrophoresis IgAk
Uric acid/creatinine o1.0 0.6
m, monoclonal; NA, not available on patient presentation; HS, high sensitivity.
Figure 1 | Histologic and serologic data. Bone marrow biopsy
(Wright Giemsa stain) showing 90% plasma cells, 15/20 (75%) of
which were atypical. Note a preponderance of mature-appearing
plasma cells with eccentric nuclei (arrow).
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Figure 2 | Histologic and serologic data. Renal biopsy: Paraffin
sections (light microscopy, top), stained weakly positive with
periodic acid–Schiff (PAS) and brightly eosinophilic with
hematoxylin and eosin (H&E). Note protein casts in tubular
lumens. Frozen sections (immunofluorescence, bottom) reacted
with antibodies to k- and l-light chains show predominant
staining of tubular casts for k-light chains.
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per 100 ml). Peripheral edema (2þ to the knees) and
proteinuria (2.7 g day1) were present. Corrected SCa level
was 8.7 mg per 100 ml and urinary uric acid-to-cr ratio was
0.7 (urate nephropathy considered if ratio 41). After volume
expansion and bicarbonate alkalinization of urine, the patient
underwent a second series (12 alternate day sessions) of
plasmapheresis with albumin. The objective of treatment was
a reduction in sFLC level and recovery of renal function.
Following plasmapheresis, there was a decrease in serum
IgA level to 45 mg per 100 ml, k-sFLCs to 5.3 mg per 100 ml,
and Scr to 4 mg per 100 ml (Figure 3). Four years after
diagnosis of MM, Scr level was stable at 2.6 mg per 100 ml.
Serial skeletal surveys remained negative.
At his most recent hospital visit (March 2007) prompted
by pulmonary infection, laboratory findings showed progres-
sive disease. A severe reduction in serum Ig levels prompted
administration of intravenous Ig. In May 2007, once infec-
tion had been treated, therapy was initiated with lenolido-
mide and dexamethasone concomitant with volume repletion
and urine bicarbonate alkalinization.
RENAL BIOPSY FINDINGS
Paraffin sections (light microscopy) stained with hematoxylin
and eosin, periodic acid–Schiff, trichrome, and silver showed
the renal cortex to contain 61 glomeruli, 50 of which
were globally sclerotic or obsolescent. Most of the glomeruli
revealed periglomerular fibrosis. The remaining glomeruli
were normal in size and in cellularity. The capillary walls were
normal in thickness and contour. The tubulointerstitial
compartment had moderate acute tubular injury, with
blebbing of the apical cytoplasm. Vacuolizations as well as
focal flattening of the epithelium were identified. Occasional
intratubular, weakly periodic acid–Schiff-positive casts were
noted. Some casts had a dense, angulated, and ‘fractured’
appearance, and were surrounded by a cellular reaction.
There was a patchy interstitial fibrosis and tubular atrophy
involving approximately 50% of the parenchyma in the
areas of globally sclerotic glomeruli. A moderate infiltrate
of macrophages and giant cells surrounded the casts.
Eosinophils were rarely present. Neutrophilic tubulitis was
not present. Immunofluorescence showed the renal cortex to
contain six glomeruli, five of which were globally sclerotic.
Occasional intratubular casts were noted, some of which
were positive for k- but negative for l-light chains. IgG, IgM,
IgA, C1q, and albumin were negative. Electron microscopy
showed glomerular basement membranes to be of normal
thickness. Electron densities were rarely noted within
paramesangial and the glomerular basement membrane.
Podocytes were acutely injured and revealed focal foot-
process effacement involving 20% of the area studied.
DISCUSSION
Renal disease in multiple myeloma
MM is a hematopoietic malignancy of terminally differen-
tiated plasma cells in the bone marrow. The incidence of 4
per 100 000 accounts for 10% of all hematological malig-
nancies.1 It occurs most often in the elderly: 68% of patients
are above 65 years, 15% are 60–65 years, 15% are 59 years or
younger, and fewer than 2% are younger than age 40. This
age distribution has profound negative implications, since in
these patients aggressive treatment, such as high-dose
chemotherapy and peripheral blood stem cells or bone
marrow transplantation, may not be well tolerated.2 In two
large biopsy series, the incidence of renal insufficiency in 869
and 141 patients with MM was 55 and 56%, respectively,3,4 a
complication linked to higher mortality, in part because renal
failure further limits some chemotherapeutic options.
Renal failure (RF) has been shown to significantly shorten
survival, but if renal function recovers, the effect is reversible.
In previous studies, recovery of renal function has been
reported in up to 58% of cases, depending on the etiology of
the RF.5,6 The most frequent renal pathologies are as follows:
cast nephropathy occurring in up to 55% of cases, Ig light-
chain-associated disease with amyloidosis in 30% of cases,
light-chain deposition disease in 19%, and interstitial
nephritis in 10% of patients with MM.7,8 Other renal
pathological manifestations of immunoglobulin diseases
include cryoglobulinemic glomerulonephritis, proliferative
glomerulonephritis, crystalline nephropathy, and fibrillary/
immunotactoid glomerulonephritis9 (Table 2a). More than
one histological pattern can coexist in the same kidney. For
this reason, clinical presentation may differ from the expected
classical clinical findings (Table 2b), making differential diag-
nosis of renal disease in MM vast, and diagnosis impossible
without renal biopsy.
The clinical entity of acute tubular necrosis is frequently
seen either alone or with other renal pathologies. The most
common combinations are cast nephropathy with acute
tubular necrosis or with monoclonal immunoglobulin depo-
sition disease.10,11 In the following series, patients with cast
nephropathy had coexisting light-chain deposition disease:
Lin et al.,10 n¼ 34, 11%, Paueksakon et al., n¼ 20,12 1%, and
376
1329
73
1180
1917
2403
11345
9.75.3
2.6
3.7
5.7
7.5
3.7 4
0
500
1000
1500
2000
2500
3000
3/14/20078/12/20067/11/20065/26/20063/16/20062/18/2006
Date
Se
ru
m
 le
ve
ls 
fo
r I
gA
 a
nd
 κ
 
lig
ht
 c
ha
in
s
(m
g p
er 
10
0 m
l)
0
1
2
3
4
5
6
7
8
Se
ru
m
 c
re
at
in
in
e 
(m
g p
er 
10
0 m
l) Serum IgA
κ sFLC
Creatinine
Figure 3 | Histologic and serologic data. Clinical follow-up: The
effect of plasmapheresis on Scr, serum IgA, and sFLC levels. The
arrows indicate the start of the plasmapheresis series.
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Buxbaum and co-workers13, n¼ 26, 5%. In the study by
Lin et al.10, patients with cast nephropathy and monoclonal
immunoglobulin deposition disease had a significant survival
disadvantage over the entire 40 month follow-up.
MCN is the most common cause of RF in patients
with MM. Among the many patterns of renal involvement
by plasma cell dyscrasias, MCN differs from others in that the
pathophysiological mechanism involves mainly intra-tubular
rather than intra-parenchymal paraprotein deposition.
MCN refers to acute or chronic renal failure caused by the
excessive production of monoclonal k- or l-light chains.
Light chains (22.5–31 kDa) are freely filtered across the
glomerulus and then reabsorbed and catabolized by proximal
tubular epithelial cells.14 In myeloma patients, up to 85 g of
monoclonal light chains may be synthesized, in comparison
with less than 30 mg produced in a healthy person. In the
setting of plasma cell dyscrasias, the overproduction of light
chains results in excessive amounts of filtered, intraluminal,
toxic sFLCs, leading to proximal tubular injury. The accumu-
lation within the proximal tubular cell may interfere
with lysosomal function.15 The quantity of light chains in
the tubular filtrate often exceeds the maximum tubular
reabsorptive capacity, providing a substrate for binding and
aggregation with the Tamm–Horsfall protein (THP), a heavily
glycosylated protein synthesized only in the apical cell
membrane and secreted in the medullary thick ascending
limb of the loop of Henle. The intrinsic affinity of the
light chains to THP, as well as the quantity, influences
cast formation. The diagnosis of cast nephropathy is based
on demonstration of eosinophilic tubular casts in the
distal nephron that are composed of either Ig light chains,
intact Ig, and/or other proteins, including THP. The casts
are surrounded by macrophages and giant cells. These casts
are associated with tubular rupture and when this occurs,
this results in interstitial nephritis. In vivo and in vitro animal
studies in which nephrotoxic light chains were infused into
the rat nephron, have demonstrated that a loop diuretic can
enhance cast formation.16 Indirectly, hypercalcemia causing
renal vasoconstriction, hyperuricemia, infection, dehydra-
tion, as well as exogenous nephrotoxic drugs, such as non
steroidal anti-inflammatory agents and iodinated contrast
media, are other notable precipitants of RF.17
Median survival in patients with myeloma is 36 months,
with a 5-year survival of 18–27%.1,18 RF is the most common
cause of death second only to infection. Patients with Scr
level p1.4 mg per 100 ml have a median survival of
44 months compared with 18 months if Scr level 1.4–2 mg
per 100 ml and o4 months if Scr is 42 mg per 100 ml.4,18
Dialysis patients with myeloma have an adjusted relative
risk for death of 2.5 times that of other dialysis patients, and
a significantly greater 2-year mortality rate (58 versus 31%).19
Median survival for patients on dialysis with MM and
Durie–Salmon stages I–III has been reported to be 18, 6, and
2 months, respectively.7 Early and aggressive management
of renal insufficiency and myeloma is therefore critical.
Management of cast nephropathy
This case presentation illustrates the clinical course of an
elderly gentleman diagnosed with MM Durie–Salmon stage
III, presenting with acute on chronic renal failure. Years
after initial diagnosis, the patient had biopsy-proven MCN,
with further deteriorating renal function. Given a median
survival of 2 months in similar patients, we now focus on the
treatment of this patient who continues to be dialysis-free
5 years after the original diagnosis.
A MM patient’s survival decreases in proportion to the seve-
rity and chronicity of RF.6 The key events in cast nephropathy
are twofold- direct toxicity of sFLCs and obstruction occur-
ring when the pathological light chains bind to THP. The
most important determinants of the obstructive component
to the pathogenesis of cast nephropathy are the quantity of
sFLCs, the affinity of sFLCs to THP, and the intravascular
volume status (urine volume and flow rate). Accordingly,
part of our therapy was aimed at maintaining volume
expansion while increasing urine output and decreasing the
pathological light-chain concentration and positive charge.
Alkalinization increases the urine pH above the isoelectric
point of cationic sFLCs, making them neutral or anionic,
thereby decreasing their affinity toward anionic THP.20
Alkalinization of urine is somewhat controversial, since not
all pathological light chains have an alkaline isoelectric point,
Table 2a | Pathological renal disease associated with
dysproteinemia
Myeloma cast nephropathy (MCN)/light-chain cast nephropathy (LCCN)
Amyloidosis (AL)
Monoclonal immunoglobulin deposition disease (MIDD): Light-chain
deposition disease (LCDD), light heavy-chain deposition disease (LHCDD),
heavy-chain deposition disease HCDD)
Renal plasma cell infiltrates
Cryoglobulinemic (membranoproliferative) GN
Proliferative GN with monoclonal immunoglobulin deposits
Crystalline GN
Immune complex-mediated GN
Fibrillary/immunotactoid GN
Crescentic GN (rare)
GN, glomerulonephritis.
Table 2b | Clinical renal disease associated with
dysproteinemia
Nephrotic syndrome
MIDD, amyloidosis, cryoglobulinemic GN
Proteinuria
Cast nephropathy, cryoglobulinemic GN, immune complex-mediated
GN, crystalline GN (variable hematuria)
Tubular injury
Proximal renal tubular acidosis
Fanconi’s syndrome
Diabetes insipidus
Hyperviscosity
Rhabdomyolysis
Pyelonephritis
Acute tubular necrosis (ATN)
Urate nephropathy
GN, glomerulonephritis; MIDD, monoclonal immunoglobulin deposition disease.
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and since heart failure can be precipitated in patients with
significant cardiac and renal failure.21 In this case, because
cardiac function was not a limitation and Scr was docu-
mented to fall with its use, it was likely a useful adjunctive
therapy. Since diuretics can lead to increased cast formation
by increasing tubular sodium concentration, decreasing
intravascular volume and flow rate in the tubules, lengthen-
ing toxic light-chain exposure, and favoring light-chain
precipitation, they were avoided in this patient. Agents that
would lead to decreased GFR and urine flow rate in
potentially volume-depleted patients, such as angiotensin-
converting enzyme inhibitors/angiotensin-receptor blockers,
were avoided.
Plasmapheresis has been in use for treating acute myeloma
kidney since 1976.22,23 The role of plasmapheresis in the
management of renal failure in myeloma patients has been
explored in three randomized, controlled trials (Table 3). We
critically evaluated evidence available from these studies
to help guide management in our patient. Zucchelli et al.
studied 29 patients with Scr level 45 mg per 100 ml who did
not respond to volume expansion. Patients were randomized
to receive HD and plasmapheresis or peritoneal dialysis
(control group). All received methylprednisolone and cyclo-
phosphamide. At baseline, 13 and 11 patients from the
plasmapheresis group and from the control group, respec-
tively, required dialysis. Renal function improved in 11 of
13 plasmapheresed patients, versus only 2 of the 14 patients
in the control group. There was also a significant difference
in 1-year survival between the two groups, 66% in the
plasmapheresis group and 28% in the control group. A
drawback to this study is that the control group received
peritoneal dialysis, whereas the experimental group received
HD. Comparing the two dialysis treatment modalities, five
patients in the peritoneal dialysis group died from infection
within the first 2 months of the study.23
In the second trial, Johnson et al. studied 21 patients, 12
of whom required dialysis at baseline. Eleven patients were
randomized to receive plasmapheresis. All patients received
melphalan, prednisone, and forced diuresis. No differences in
overall renal recovery or survival were noted (control 50%
versus plasmapheresis 64%, P¼NS). Not only was this study
severely underpowered and results not statistically significant,
but the more severe cases were in the plasmapheresis group.24
However, in a subgroup analysis of dialysis-dependent
patients, renal function recovered only in those receiving
plasmapheresis (43% in the plasmapheresis group versus
0% in the control group). These studies led the Scientific
Advisors of the International Myeloma Foundation to
formally endorse its use.25
Finally, the third, and the largest, randomized study
involving 97 patients with newly diagnosed myeloma failed
to show any benefit.26 In this study, dialysis at baseline was
less common than the previous studies, occurring in only
36% of control and 26% of plasmapheresis-receiving
patients. Renal diagnosis was not confirmed in the vast
majority of these patients, since biopsies were rarely
performed. The results showed 69% of the controls and
58% of the plasmapheresis-receiving patients gave a compo-
site outcome, which included death, dialysis dependence, and
estimated GFR o30 ml min1 1.73 m2 at 6 months. Results
were not statistically significant. Plasmapheresis appeared to
be ineffective in myeloma patients with undifferentiated RF.
Using the results of these three studies, a treatment
plan was initiated for our patient. First, because of the high
mortality rate of the peritoneal dialysis patients in Zucchelli’s
study, HD was used as renal replacement therapy.
The decision to start plasmapheresis was more difficult.
Because our patient was dialysis dependent, recovery of
renal function without plasmapheresis would be less likely,
based on Johnson’s study. On the other hand, Clark’s study
clearly showed no difference in the composite outcome. We
ultimately decided to start plasmapheresis as our patient was
more similar to those in Zucchelli and Johnson’s studies
whose renal diagnosis had been confirmed. In addition, by
using monoclonal protein (IgA and later sFLC) as markers of
therapy, our patient was insured more effective therapy and
ended up receiving more exchanges than patients in Clark’s
study. In the end however, the results of our patient were
consistent with those of Clark’s study, since estimated GFR of
our patient was only 26 ml min1 1.73 m2.
In summary, we present the case of a man with RF, secon-
dary to MCN, in a patient with relapsed MM who was treated
with plasmapheresis. This case illustrates several important
points when deciding on the appropriate treatments for
these patients. Having a biopsy-confirmed renal diagnosis
lent more support for use of plasmapheresis. In addition,
goal-directed therapy targeting the monoclonal protein may
produce better outcome. The most important question,
however, remains as to how we interpret the results. If our
patient were enrolled in Clark’s study, he would have been
Table 3 | Comparison of results from three randomized trials
Zucchelli et al. (1988) Johnson et al. (1990) Clark et al. (2005)
Control Plasma exchange Control Plasma exchange Control Plasma exchange
Number of patients 14 15 10 11 39 58
Number of patients requiring dialysis 11 (78%) 13 (87%) 5 (50%) 7 (64%) 14 (36%) 15 (26%)
Number of patients recovered from dialysis 2 (18%) 11 (85%) 0 3 (43%) 7 (47%) 13 (59%)
Mean Scr after treatment (mg per 100 ml) 7.7 (±1.9) 2.6 (±2.1) 2.3 (±1.1) 2.9 (±1.3) 3.5 (±2.9) 2.4 (±2.4)
(mmol l1) 680 (±168) 230 (±186) 200 (±100) 260 (±120) 314 (±256) 215 (±215)
Scr, serum creatinine.
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labeled a treatment failure, yet he would have been a success
in Zucchelli and Johnson’s studies. While having an estimated
GFR o30 ml min1 1.73 m2 has its disadvantages, it is
certainly a superior alternative to dialysis. Our patient has
remained dialysis-free. He was therefore able to receive
the latest myeloma therapy at the recommended doses, which
has extended his lifespan. In this case, by Clark’s criteria, he
would be deemed a treatment failure; his outcome was in fact
a great victory in terms of quality and years of life.
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